Kim et al. [27,28] showed that non-tumor-bearing (NT), recombinant adeno-associated virus (rAAV) vector-treated GSDIa mice (AAV-NT mice) expressing various levels (0.9–63%) of normal hepatic glucose-6-phosphatase-α had active hepatic AMP-activated protein kinase (AMPK)/sirtuin-1 (SIRT1) signaling pathways after 90 weeks of treatment, unlike untreated mice. Here, SIRT1 is linked to neoplasm.